Artelo Biosciences Highlights Promising Preclinical Results for Depression Treatment

Artelo Biosciences shares are trading higher after the company announced positive preclinical efficacy of its drug candidate ART12.11 in a stress-induced depression model, demonstrating significant antidepressant-like activity and cognitive benefits.